Twin Capital Management Inc. Invests $521,000 in Teleflex Incorporated (NYSE:TFX)

Twin Capital Management Inc. purchased a new position in Teleflex Incorporated (NYSE:TFX) in the 4th quarter, HoldingsChannel reports. The fund purchased 2,927 shares of the medical technology company’s stock, valued at approximately $521,000.

A number of other hedge funds also recently bought and sold shares of TFX. Headlands Technologies LLC purchased a new stake in shares of Teleflex during the fourth quarter valued at approximately $29,000. Avior Wealth Management LLC boosted its stake in Teleflex by 81.2% during the 4th quarter. Avior Wealth Management LLC now owns 279 shares of the medical technology company’s stock valued at $50,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc increased its holdings in shares of Teleflex by 238.5% in the 4th quarter. IFP Advisors Inc now owns 308 shares of the medical technology company’s stock worth $55,000 after purchasing an additional 217 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Teleflex by 38.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company’s stock worth $61,000 after purchasing an additional 94 shares during the last quarter. Finally, R Squared Ltd purchased a new position in shares of Teleflex in the fourth quarter worth $64,000. Institutional investors own 95.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on TFX. Raymond James downgraded Teleflex from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company reduced their price target on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. StockNews.com downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research report on Wednesday, March 12th. Finally, Citizens Jmp lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teleflex has a consensus rating of “Hold” and an average target price of $182.63.

Teleflex Stock Performance

NYSE:TFX opened at $130.95 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The stock has a 50-day simple moving average of $153.81 and a two-hundred day simple moving average of $185.45. The firm has a market capitalization of $6.07 billion, a PE ratio of 26.03, a P/E/G ratio of 1.73 and a beta of 1.19. Teleflex Incorporated has a 52-week low of $127.18 and a 52-week high of $249.91.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, March 7th were given a dividend of $0.34 per share. The ex-dividend date was Friday, March 7th. This represents a $1.36 annualized dividend and a dividend yield of 1.04%. Teleflex’s payout ratio is 95.77%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.